REIMBURSEMENT FOR RADIO/MICROWAVE-BASED BPH TREATMENTS KEY TO WIDESPREAD USE; INSURERS LIKELY TO TIE COVERAGE DECISIONS TO PUBLICATION OF DURABILITY DATA
This article was originally published in The Gray Sheet
Executive Summary
Widespread acceptance by the urology community, particularly office-based physicians, of less-invasive technology for treatment of benign prostatic hyperplasia (BPH) hinges on favorable reimbursement decisions by insurance companies and the Health Care Financing Administration, a four-member panel of urologists told attendees of an Oct. 30 Dain Bosworth urology symposium in Boston.
You may also be interested in...
BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875
EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.
BPH Treatment Devices To Be Reimbursed By HCFA At Approximately $1,875
EDAP expects that the lower cost of its Prostatron microwave-based system for treating benign prostatic hyperplasia will make the product more attractive than competing devices now that therapy has been assigned an ambulatory payment classification (APC) code with a set reimbursement level.
ArgoMed Seeks Partner To Distribute Low-Cost BPH Treatment Device
ArgoMed is planning to put its Thermoflex system for treatment of benign prostatic hyperplasia in the hands of a distribution partner capable of clearing a path into an already crowded market.